Search

Displaying results 2751 - 2760 of 5898 in total
  1. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.

  2. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending. A...

  3. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. … Structurally, tetraethylammonium is positively charged due to its central quaternary ammonium.

  4. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx. Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 20...

  5. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    Due to its ability to reduce oxidative damage and improve ATP production, idebenone was originally investigated for its potential use in Alzheimer's Disease and other cognitivie disorders [A19769]. … More specifically, idebenone is thought to transfer electrons directly to complex III of the mitochondrial ETC, thereby circumventing complex I and restoring cellular energy (ATP) generation [L885].

  6. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  7. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]

  8. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. … This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth.

    Synonyms: 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
  9. Drug

    Betaxolol

    go.drugbank.com/drugs/DB00195
    ApprovedInvestigational

    A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

    Products: IOBET EYE DROPS 0.5% W/V
  10. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body.